Arch Pathol Lab Med. 2010 Aug;134(8):1106-7. doi: 10.5858/2009-0731-RA.1.
Abstract UroVysion (Abbott Molecular Inc, Des Plaines, Illinois) is a US Food and Drug Administration-approved test for the diagnosis of urothelial carcinoma. Although widely used, there are a variety of different ways to evaluate and interpret the test, and questions remain about the test's cost effectiveness and reproducibility in actual clinical practice. I suggest that the College of American Pathologists has a unique opportunity to create educational programs focusing on borderline or difficult urine cytology and UroVysion samples to provide data upon which to make evidence-based decisions concerning the best use of these tests.
摘要 UroVysion（雅培分子公司，伊利诺伊州德斯普兰斯）是美国食品和药物管理局批准的用于诊断尿路上皮癌的检测方法。尽管该检测已被广泛应用，但在实际临床实践中，对于该检测的评估和解释方法多种多样，其成本效益和可重复性仍存在争议。我认为，美国病理学家学院有机会创建专注于边界性或困难性尿液细胞学和 UroVysion 样本的教育项目，提供数据，以便就这些检测方法的最佳使用做出基于证据的决策。
